Atripla

Antiretroviral Therapy, HIV test negative, HIV Infections + 12 more
Treatment
2 FDA approvals
20 Active Studies for Atripla

What is Atripla

EmtricitabineThe Generic name of this drug
Treatment SummaryEfavirenz (brand names Sustiva® and Stocrin®) is a medication used to treat HIV-1. When used in combination with other antiretroviral medications, it can reduce the risk of HIV transmission from high-risk exposures. It is usually combined with lamivudine and either zidovudine or tenofovir for HIV infection that has not previously been treated. Efavirenz is part of a highly active antiretroviral therapy (HAART) regimen for HIV treatment.
Emtrivais the brand name
image of different drug pills on a surface
Atripla Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Emtriva
Emtricitabine
2003
131

Approved as Treatment by the FDA

Emtricitabine, also called Emtriva, is approved by the FDA for 2 uses including HIV and adults and pediatric patients weighing at least 17 kg .
HIV
Helps manage Human Immunodeficiency Virus Type 1 (HIV-1) Infection
adults and pediatric patients weighing at least 17 kg

Effectiveness

How Atripla Affects PatientsEfavirenz is a type of medicine used to treat HIV infections. It is usually taken as part of a three-drug regimen that includes another type of HIV medication, such as lamivudine, stavudine or zidovudine, and a protease inhibitor. It was originally approved for use in patients who had not responded to treatment with zidovudine.
How Atripla works in the bodyEfavirenz works to stop HIV from reproducing by stopping an enzyme called reverse transcriptase from copying viral RNA. This stops the virus from making new copies of itself. Though human DNA polymerase is less likely to be affected by efavirenz, this may still be a cause of some of the drug's side effects.

When to interrupt dosage

The measure of Atripla is contingent upon the indicated condition. The amount of dosage will be contingent upon the technique of delivery (e.g. Tablet or Capsule - Oral), as shown in the table beneath.
Condition
Dosage
Administration
Antiretroviral Therapy
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
HIV test negative
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
HIV Infections
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
HIV Transmission
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
Anti-Retroviral Agents
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
adults and pediatric patients weighing at least 17 kg
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
not requiring CYP3A inhibitors
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
treatment failure
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral
Sexual Behavior
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution, Solution - Oral

Warnings

Atripla Contraindications
Condition
Risk Level
Notes
HIV
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Emtricitabine may interact with Pulse Frequency
There are 20 known major drug interactions with Atripla.
Common Atripla Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Emtricitabine.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Emtricitabine.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Emtricitabine.
Cefradine
Minor
The excretion of Cefradine can be decreased when combined with Emtricitabine.
Estrone sulfate
Minor
The excretion of Estrone sulfate can be decreased when combined with Emtricitabine.
image of a doctor in a lab doing drug, clinical research

Atripla Novel Uses: Which Conditions Have a Clinical Trial Featuring Atripla?

44 active studies are currently assessing the potential of Atripla to provide Antiretroviral Therapy.
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Sexual Behavior
10 Actively Recruiting
Not Applicable, Phase 4
HIV Infections
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting
treatment failure
0 Actively Recruiting
adults and pediatric patients weighing at least 17 kg
0 Actively Recruiting
HIV Transmission
0 Actively Recruiting
Obesity
643 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3
Antiretroviral Therapy
0 Actively Recruiting
HIV
0 Actively Recruiting
Obesity
0 Actively Recruiting
not requiring CYP3A inhibitors
0 Actively Recruiting
HIV test negative
0 Actively Recruiting
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Obesity
0 Actively Recruiting

Atripla Reviews: What are patients saying about Atripla?

5Patient Review
8/31/2015
Atripla for HIV
This treatment saved my life. When I started it, my CD4 was less than 600 and my copy count was in excess of 350K. Within 6 months, my CD4 was up to 970, and my viral load was undetectable, and I've remained this way for over 2 years.
5Patient Review
1/19/2018
Atripla for HIV
Atripla is most effective when taken before bed. The side effects are strongest in the first few weeks, but they should dissipate after that.
5Patient Review
6/4/2014
Atripla for HIV
I've only been on Atripla for 4 weeks, but it's going well so far. I had slight dizziness on the first day and sickness on day 3, but I'm attributing that to taking 2 ibuprofen for sinus pain. My girlfriend caught HIV from me and she's been on Atripla for 10 months now. Her viral load is undetectable now, which is great news.
5Patient Review
2/9/2014
Atripla for HIV
5Patient Review
3/22/2014
Atripla for HIV
5Patient Review
2/28/2017
Atripla for HIV
I've been on Atripla for over five years with no problems. My labs are great, but I'm suddenly feeling more symptoms. Has anyone else experienced this?
4.7Patient Review
8/20/2015
Atripla for HIV
Atripla has been working well for me for almost three years now. The only side effects I've noticed are a light dizziness, some irritability, and diarrhea if I eat or drink within 12 hours of taking the medication. Additionally, I sometimes have strange dreams.
4.7Patient Review
9/2/2014
Atripla for HIV
I felt a little dizzy for the first few days, but that passed. I also had very vivid dreams--that was interesting. After one month, my viral load went from 35k to <20--so it's working well! The only downside is that coffee makes me have to use the restroom immediately.
4.7Patient Review
5/5/2014
Atripla for HIV
This medication can cause obesity, so doctors should warn their patients that they may need to change their eating habits.
4.3Patient Review
11/21/2014
Atripla for HIV
I constantly battle dry skin, and lately I've been struggling with an increased appetite which has lead to weight gain. On top of that, I'm pretty much always dealing with some sort of yeast infection. So, needless to say, I'm really hoping to find a less toxic solution soon.
4.3Patient Review
6/30/2014
Atripla for HIV
I saw a significant increase in my CD4 and decrease in my viral load after just three months of treatment. The only downside was the severe drowsiness I felt for about 24 hours every day, as well as some vivid dreams during the first few weeks. Overall, though, it was worth it and I'm hoping to be undetectable at my six month mark.
3.7Patient Review
2/8/2018
Atripla for HIV
I've been on Atripla for six years, but some of the side effects are really tough to deal with. My sleep quality has decreased dramatically, and I often feel bad a few hours after taking the pill. Additionally, I've been feeling depressed more frequently, and my memory isn't what it used to be. Does anyone know of a better medicine than Atripla?
3.7Patient Review
7/29/2020
Atripla for HIV
After taking this drug for ten years, I started to experience intense psychological problems. Additionally, the osteopenia in my bones got worse and my lipodystrophy (a side effect of many HIV medications) worsened. There are much better alternatives to Atripla out there that don't come with these nasty side effects.
3.7Patient Review
6/22/2014
Atripla for HIV
I'm not sure if there's a difference between the 300 mg and 245 mg versions of this drug; however, both seem to work well for me.
3Patient Review
3/12/2022
Atripla for HIV
I had some physical problems after using this treatment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about atripla

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why is Atripla discontinued?

"The branded version of Atripla will be discontinued at the end of 2021 because there is not a high demand for it."

Answered by AI

What is Atripla tablets used for?

"This lowers your chance of getting HIV complications (such as new infections, cancer) and increases your life span.

This product contains 3 different medications: efavirenz, emtricitabine, and tenofovir. These medications are used to help control HIV infection. They work by decreasing the amount of HIV in the body, which helps the immune system to work better. This in turn lowers the person's chance of developing HIV complications, and increases their life span."

Answered by AI

Is Atripla still prescribed?

"Atripla and Truvada are both approved for use in people of any age, as long as they weigh at least 88 pounds (40 kilograms) and 37 pounds (17 kilograms) respectively. Truvada is also approved for the prevention of HIV."

Answered by AI

What are the long term side effects of Atripla?

"If you have kidney problems, you may experience increased thirst and urination, muscle pain or weakness. If you have liver problems, you may experience swelling around your midsection, right-sided upper stomach pain, loss of appetite, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes)."

Answered by AI

Clinical Trials for Atripla

Image of UConn Health in Farmington, United States.

Digital Exercise Prescription Tool for Cardiovascular Disease

18 - 64
All Sexes
Farmington, CT
The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.
Waitlist Available
Has No Placebo
UConn Health (+2 Sites)Linda S Pescatello, PhD
Have you considered Atripla clinical trials? We made a collection of clinical trials featuring Atripla, we think they might fit your search criteria.Go to Trials
Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Image of The Weight Control and Diabetes Research Center of The Miriam Hospital & Brown University in Providence, United States.

Self-Monitoring Strategies for Obesity

18 - 70
All Sexes
Providence, RI
This clinical trial is focused on testing dietary self-monitoring strategies used in behavioral obesity treatment. The goal is to determine which self-monitoring strategies are most useful for whom, at which points in treatment, and under what circumstances. Researchers will provide a 24-week online behavioral obesity treatment program, and will randomize participants to use one of 5 dietary self-monitoring strategies every two weeks. The five strategies include: recording all food and drink consumed and corresponding energy intake (i.e., "calories") on 7 days per week; recording all food and drink consumed and corresponding energy intake (i.e., "calories") on 3 days per week; self-monitoring of dietary lapses (i.e. any eating/drinking likely to cause weight gain or put weight loss at risk); smartwatch-based monitoring of energy intake (i.e., "calories"); and self-monitoring of body weight only via smart scale. Participants will: * Follow a 24-week online program for weight loss and health improvement * Use the assigned self-monitoring strategy every two weeks * Meet with the researchers periodically via online video call and provide research data by answering questions via periodic online surveys.
Recruiting
Has No Placebo
The Weight Control and Diabetes Research Center of The Miriam Hospital & Brown UniversityGraham Thomas, PhD
Have you considered Atripla clinical trials? We made a collection of clinical trials featuring Atripla, we think they might fit your search criteria.Go to Trials
Have you considered Atripla clinical trials? We made a collection of clinical trials featuring Atripla, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security